Share
Dr. Ruxandra Draghia-Akli
Novavax, Inc, a global leader in protein-based vaccines utilizing its Matrix-M™ adjuvant technology, has named Ruxandra Draghia-Akli, MD, PhD, as its new Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli will join the company in November 2024, bringing over two decades of expertise in vaccines and public health.
Dr. Draghia-Akli has an extensive background in both large pharmaceutical and biotech sectors. She most recently served as Global Head of Public Health R&D at Johnson & Johnson, leading key initiatives in areas such as Dengue, tuberculosis, and coronaviruses. Her experience includes senior roles at Merck, where she contributed to the development of vaccines for Ebola, pneumococcal disease, and HPV. She has also worked with the European Commission on research and innovation policy.
"Ruxandra’s extensive experience makes her the ideal leader to shape Novavax's R&D strategy as we expand our pipeline," said John C. Jacobs, President and CEO of Novavax. "Her leadership will be instrumental in driving forward our technology to address pressing public health needs."
Dr. Draghia-Akli will succeed Filip Dubovsky, MD, MPH, who retired in July 2024 but will continue as an Executive Advisor.
